<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55186">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387710</url>
  </required_header>
  <id_info>
    <org_study_id>BWH-2012P000956B</org_study_id>
    <nct_id>NCT02387710</nct_id>
  </id_info>
  <brief_title>Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea</brief_title>
  <acronym>TESSA</acronym>
  <official_title>Inducing Slow Wave Sleep to Treat Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is common and has major health implications but treatment
      options are limited. Interestingly, the severity of OSA is profoundly reduced in deep sleep
      (called &quot;slow wave sleep&quot;), potentially via an increase in the stimulus required to arouse
      from sleep. Here the investigators test the idea that the medication called &quot;tiagabine&quot;
      improves slow wave sleep and reduces OSA severity. The investigators will also test whether
      tiagabine raises the arousal threshold (more negative esophageal pressure), and whether
      detailed OSA &quot;phenotyping&quot; characteristics can predict the improvement in OSA severity with
      this intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study tests the primary hypothesis that tiagabine improves sleep apnea severity
      in patients with moderate-to-severe sleep apnea (apnea hypopnea index measured in supine
      non-REM sleep; hypopneas defined by 3% desaturation or arousal). The investigators test
      three secondary hypotheses that tiagabine:

        1. increases the proportion of total sleep time in slow wave sleep

        2. raises the non-REM arousal threshold (more negative esophageal pressure) via (1).

        3. is preferentially effective in patients whose OSA phenotype predicts that an increase
           in the arousal threshold is sufficient to resolve OSA versus those without such
           favorable physiology. Favorable physiology is defined here as having a low ventilatory
           drive at which stable breathing is theoretically feasible (&quot;stable Vdrive&quot; is &lt;100%
           above eupneic ventilatory drive) due to any combination of a &quot;high&quot; upper airway muscle
           response, &quot;good&quot; passive anatomy (high Vpassive), and &quot;low&quot; steady-state loop gain (see
           Owens RL et al SLEEP 2014; Wellman A et al J Appl Physiol 2011, 2013; Eckert DJ et al
           2013 AJRCCM).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in apnea hypopnea index (hypopnea criteria: 3% desaturation or arousal)</measure>
    <time_frame>1 night</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in slow wave sleep (% total sleep time)</measure>
    <time_frame>1 night</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>increase in arousal threshold (esophageal pressure swing)</measure>
    <time_frame>1 night</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiagabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiagabine PO 12 mg before sleep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo PO before sleep</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiagabine</intervention_name>
    <description>GABA reuptake inhibitor</description>
    <arm_group_label>Tiagabine</arm_group_label>
    <other_name>Gabitril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed OSA (moderate-to-severe; apnea hypopnea index &gt;15 events/hr)

        Exclusion Criteria:

          -  History of seizures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sleep Disorders Research Program Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 14, 2016</lastchanged_date>
  <firstreceived_date>March 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>David Andrew Wellman</investigator_full_name>
    <investigator_title>Director, Sleep Disordered Breathing Laboratory</investigator_title>
  </responsible_party>
  <keyword>arousal threshold</keyword>
  <keyword>phenotype</keyword>
  <keyword>tiagabine</keyword>
  <keyword>slow wave sleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tiagabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
